Last reviewed · How we verify
NCT05724615
Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening (Missing Lipids)
NA trial testing Outreach + Bulk ordering in Atherosclerotic Cardiovascular Disease in 1,000 participants. Completed in 7 December 2023.
7 September 2023
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 1,000 |
| Start date | 5 June 2023 |
| Primary completion | 7 September 2023 |
| Estimated completion | 7 December 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Outreach + Bulk ordering
- Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance
Conditions studied
- Atherosclerotic Cardiovascular Disease — all drugs for Atherosclerotic Cardiovascular Disease →
Sponsor
University of Pennsylvania
Who can join
Adults 20 to 75, any sex, with Atherosclerotic Cardiovascular Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
We aim to evaluate different approaches to increase Lipid screenings among primary care patients at Penn Medicine. A randomized trial will test the effectiveness of bulk ordering, outreach via mailed letters, and text-based reminders with scheduling assistance for patients needing a lipids panel. We will observe the number of completed panels after 3 and 6 months.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening: A Randomized Clinical Trial.
Pollak C, Parambath A, Coratti S, Norton L, et al · · 2025 · cited 1× · PMID 39879069 · DOI 10.1001/jamacardio.2024.5281
Verify or expand the search:
- PubMed search for NCT05724615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atherosclerotic Cardiovascular Disease
Currently open trials in the same condition.
- NCT07034690 — Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dy · Phase 4 · recruiting
- NCT06424860 — Fish Oil, Metformin and Heart Health in PCOS · Phase 1 · recruiting
- NCT06962488 — Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure · NA · recruiting
- NCT07037433 — Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov · Phase 3 · recruiting
- NCT06875973 — Pelacarsen Roll-over Extension Program · Phase 3 · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05724615 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing